Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Prolacta Bioscience Inc
EIR
•Prolacta Bioscience Inc•July 30, 2021

Prolacta Bioscience Inc – FDA EIR, Jul 30, 2021

Record Details

Prolacta Bioscience Inc. underwent a routine FDA surveillance inspection at its City of Industry, CA facility from July 26-30, 2021. The inspection covered good manufacturing practices and Infant Formula regulations, aligning with Compliance Programs for Infant Formula, Preventive Controls, Sanitary Human Food Operations, and Nutritional Labeling. Notably, no formal FDA-483 Inspectional Observations were issued. However, the inspection highlighted several areas for discussion and potential improvement. These included enhancing environmental monitoring for compressed air by increasing data frequency beyond monthly tests, and improving pasteurization batch records to include actual temperature readouts from thermometers, rather than just 'yes/no' confirmations. Further discussions recommended identifying clear operating ranges for parameters like pressure and flow in Ultrafiltration (UF) process records. The FDA also advised routine challenge testing of the labeling machine to ensure it effectively identifies and rejects mislabeled products, along with consistent calibration of critical instruments like mixer sensors. Management was encouraged to re-evaluate the manual mineral addition process due to its high-risk nature involving extensive handling and product exposure, considering changes to mitigate potential contamination. This review also ties into the firm's ongoing evaluation of a S. aureus enterotoxin testing program, with a suggestion to assess if the mineral addition step influences S. aureus viability. The company had previously identified that annual GMP training for 2020 was not completed due to COVID, for which they had already created an internal Observation Report. No samples were collected, and no refusals were encountered during this inspection.

Company
Prolacta Bioscience Inc
Inspection date
July 30, 2021
Product type
Biologics
Office
Los Angeles District Office
People
  • Greg K. Keshishyan (investigator)
  • Elizabeth P. Mayer
  • Dena L. Jacobs (investigator)
  • Alexandra B. Pitkin (Investigator)
View Company Profile

ID · 6211d575-8717-497e-90cc-c7f3fda0a6df

Violation Codes3
21 CFR 106.621 CFR 21121 CFR 820.50

Full citation text and observation details available on the Dashboard.

Other documents for Prolacta Bioscience Inc
  • EIR - 2019-11-22November 22, 2019
  • EIR - 2014-03-25March 25, 2014

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Prolacta Bioscience Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.